Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 6, 2020
- Accepted August 4, 2020
- First Published September 4, 2020.
Article Versions
- Previous version (September 4, 2020 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Sachin Kapur, MD, MS,
- Christina Vaughan, MD, MHS,
- Jacob Hawkins, BS,
- Glenn Stebbins, PhD and
- Deborah Hall, MD, PhD
- Sachin Kapur, MD, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Speaker for Teva, Acadia, Kyowa Kirin, and US World Meds.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christina Vaughan, MD, MHS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) University of Colorado Anschutz Medical Center, Department of Neurology Interdepartmental Grant
1) Adira Foundation Fast-Track Grant: COVID-19
NONE
NONE
NONE
NONE
NONE
NONE
- Jacob Hawkins, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Glenn Stebbins, PhD and
1. Ultragenyx Pharmaceutical 2. Medgenesis 3. Cleveland Clinic Foundation
NONE
1. International Parkinson and Movement Disorder Society - Travel 2. Dystonia Coalition - Travel 3. American Academy of Neurology - Honoraria 4. Michael J. Fox Foundation for Parkinson's Research - Honoraria 5. Food and Drug Administration - Honoraria 6. National Institutes of Health - Honoraria 7. TOXINS - Travel 8. American Society for Experimental Neurotherapeutics - Travel
NONE
NONE
NONE
NONE
1. Acadia Pharmaceuticals 2. Adamas Pharmaceuticals, Inc. 3. Ceregene, Inc. 4. CHDI Management, Inc. 5. Ingenix Pharmaceutical Services (i3 Research) 6. Neurocrine Biosciences, Inc. 7. Pfizer, Inc. 8. Tool-4-Patient
NONE
NONE
NONE
NONE
1. US Army Medical Research and Materiel Command, PR161108, Co-I, 2017- 2022
NONE
1. Michael J. Fox Foundation for Parkinson's Research 2. CHDI 3. Dystonia Coalition 4. International Parkinson and Movement Disorder Society 5. CBD Solution
NONE
NONE
NONE
NONE
NONE
NONE
- Deborah Hall, MD, PhD
National Fragile X Foundation Scientific Advisory Board
NONE
NONE
Associate Editor of Neurology Today
NONE
NONE
NONE
Fujifilm
NONE
NONE
NONE
Abbvie, Biogen, Biohaven, Neurocrine
NIH NS082416, NS074343, NS083054
NONE
Parkinson Foundation, Huntington's Disease Society of America, CHDI
NONE
NONE
NONE
NONE
NONE
NONE
- Department of Neurological Sciences, Rush University, Department of Neurological Sciences, Chicago, IL.
- Correspondence
Mr. Hawkins Jacob_Hawkins{at}rush.edu
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.